Therapeutics of Alzheimer's disease: Past, present and future
Alzheimer's disease (AD) is the most common cause of dementia worldwide. The etiology is
multifactorial, and pathophysiology of the disease is complex. Data indicate an exponential …
multifactorial, and pathophysiology of the disease is complex. Data indicate an exponential …
Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions
A Abeysinghe, R Deshapriya, C Udawatte - Life sciences, 2020 - Elsevier
Alzheimer's disease (AD) is a neurodegenerative disorder and is identified as the most
common cause for dementia. Despite huge global economic burden and the impact on the …
common cause for dementia. Despite huge global economic burden and the impact on the …
Therapies for Alzheimer's disease.
I Melnikova - Nature Reviews Drug Discovery, 2007 - nature.com
Alzheimer's disease (AD) is a devastating neurological disorder that affects more than 37
million people worldwide1. The economic burden of AD is massive; in the United States …
million people worldwide1. The economic burden of AD is massive; in the United States …
Alzheimer's disease: key insights from two decades of clinical trial failures
CK Kim, YR Lee, L Ong, M Gold… - Journal of Alzheimer's …, 2022 - content.iospress.com
Given the acknowledged lack of success in Alzheimer's disease (AD) drug development
over the past two decades, the objective of this review was to derive key insights from the …
over the past two decades, the objective of this review was to derive key insights from the …
Recent developments in Alzheimer's disease therapeutics
MS Rafii, PS Aisen - BMC medicine, 2009 - Springer
Alzheimer's disease is a devastating neurological disorder that affects more than 37 million
people worldwide. The economic burden of Alzheimer's disease is massive; in the United …
people worldwide. The economic burden of Alzheimer's disease is massive; in the United …
Alzheimer's disease: the challenge of the second century
DM Holtzman, JC Morris, AM Goate - Science translational medicine, 2011 - science.org
Alzheimer's disease (AD) was first described a little more than 100 years ago. It is the most
common cause of dementia with an estimated prevalence of 30 million people worldwide, a …
common cause of dementia with an estimated prevalence of 30 million people worldwide, a …
Pharmacotherapy of Alzheimer's disease: current and future trends
WJ Geldenhuys, AS Darvesh - Expert review of neurotherapeutics, 2015 - Taylor & Francis
Alzheimer's disease (AD) and its related dementia has shown an alarming rise in the global
population. Although considerable efforts have been made to develop effective therapeutic …
population. Although considerable efforts have been made to develop effective therapeutic …
Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease
Y Madav, S Wairkar, B Prabhakar - Brain research bulletin, 2019 - Elsevier
Alzheimer's disease (AD) has been a global concern for years due to its severe implications
that affects the quality of life of the patients. The available line of therapy for treating …
that affects the quality of life of the patients. The available line of therapy for treating …
Aducanumab: first approval
S Dhillon - Drugs, 2021 - Springer
Aducanumab (aducanumab-avwa; Aduhelm™) is a human, immunoglobulin gamma 1
(IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of …
(IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of …
[PDF][PDF] Pathophysiology and management of Alzheimer's disease: An overview
Alzheimer's disease (AD) is the sixth-leading reason of fatality and is 70% present in all
cases of dementia. The global burden of AD is expected to accelerate from 26.6 million …
cases of dementia. The global burden of AD is expected to accelerate from 26.6 million …